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Abstract: 
Background:  
Psychiatric disorders have been hypothesized to share common etiological pathways with 
obesity, suggesting related neurobiological bases. We aimed to examine whether CRTC1 
polymorphisms were associated with major depressive disorder (MDD) and to test the 
association of these polymorphisms with obesity markers in several large case-control 
samples with MDD. 
Methods:  
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The association between CRTC1 polymorphisms and MDD was investigated in three case-
control samples with MDD (PsyCoLaus n1=3,362, Radiant n2=3,148 and NESDA/NTR 
n3=4,663). The effect of CRTC1 polymorphisms on obesity markers was then explored.  
Results:  
CRTC1 polymorphisms were not associated with MDD in the three samples. CRTC1 
rs6510997C>T was significantly associated with fat mass in the PsyCoLaus study. In fact, a 
protective effect of this polymorphism was found in MDD cases (n=1,434, β=-1.32%, 95% CI -
2.07 to -0.57, P<0.001), but not in controls. In the Radiant study, CRTC1 polymorphisms were 
associated with BMI, exclusively in individuals with MDD (n=2,138, β=-0.75 kg/m2, 95% CI -
1.30 to -0.21, p=0.007), while no association with BMI was found in the NESDA/NTR study. 
Limitations:  
Estimated fat mass using bioimpedance that capture more accurately adiposity was only 
present in the PsyCoLaus sample. 
Conclusions:  
CRTC1 polymorphisms seem to play a role with obesity markers in individuals with MDD 
rather than non-depressive individuals. Therefore, the weak association previously reported 
in the population-based samples was driven by cases diagnosed with lifetime MDD. 
However, CRTC1 seems not to be implicated directly in the development of psychiatric 
diseases. 
 
 
 
Keywords: Obesity, major depressive disorder, psychiatric disorders, psychotropic drugs, 
pharmacogenetics, genetic polymorphisms.  
4 
 
 
 
 
 
Introduction: 
Based on a growing body of evidence, it has been hypothesized that psychiatric 
disorders, such as schizophrenia and mood disorders, are causally related to or share 
common etiological pathways with obesity, suggesting that comorbid obesity and psychiatric 
disorders have related neurobiological bases (Farmer et al., 2008; Forty et al., 2014). Increased 
appetite, weight gain and obesity are common symptoms of depression (Blaine, 2008; 
Luppino et al., 2010). On the other hand, obese individuals were also found to have higher 
prevalence of depression (Luppino et al., 2010). Shared genetic factors were previously 
suggested (Afari et al., 2010; Comings et al., 1996; Rivera et al., 2012; Samaan et al., 2013), 
however, due to the pathological complexity of both conditions and the polygenic factors 
affecting them, many genetic factors are still to unravel. Additionally, due to heterogeneity 
of depression, genetic association studies could give conflicting results. One example is the 
fat mass and obesity-associated gene (FTO) for which the common rs9939609-A variant 
previously associated with increased body mass index (BMI) and obesity in several 
studies(Frayling et al., 2007; Qi et al., 2008; Scuteri et al., 2007) was shown to be negatively 
associated with depression in a meta-analysis of four large studies (Samaan et al., 2013). On 
the other hand, the same variant was found to be positively associated with depression in a 
recent large case-control study (Milaneschi et al., 2014), but this association was entirely 
driven by the atypical depression subtype (subtype characterized typically by increased 
appetite, weight gain and hypersomnia). 
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We previously showed an association between a coding single nucleotide 
polymorphism (SNP) within the CREB-regulated transcription coactivator 1 (CRTC1) gene 
(rs3746266A>G) and BMI in 3 independent psychiatric samples (brief description of these 
samples is given in the Supplementary data and is described in details in ref (Choong et al., 
2013)). Carriers of the rs3746266-G variant showed significantly protective effect against 
obesity compared to non-carriers. The sex-stratified analysis in the 3 combined psychiatric 
samples showed a protective effect for the G allele both in men and women. However, the 
strongest and most clinically relevant association was observed in women younger than 45 
years old. Although the effect was weaker, we also found a protective effect of the T allele of 
the CRTC1 rs6510997C>T (a proxy of rs3746266A>G, r2=0.7) on fat accumulation in a large 
population-based sample (CoLaus), with the strongest association again in premenopausal 
women (Choong et al., 2013).  
In animal models, we previously showed that mice lacking CRTC1 exhibit 
neurobehavioral endophenotypes related to mood disorders, depression-related behavior 
and a blunted behavioral response to antidepressants (Breuillaud et al., 2012). Crtc1 
knockout mice also developed obese features, including obesity-related metabolic 
complications, under normal diets (Altarejos et al., 2008; Breuillaud et al., 2009). Altogether, 
these findings suggest that the Crtc1 gene might play a common role in obesity and 
depression-related behavior.   
In the present study, we aimed to examine whether CRTC1 SNPs are associated with 
major depressive disorder (MDD), and to test the association of CRTC1 SNPs with obesity 
markers in several large case-control samples with MDD. The same CRTC1 SNPs 
(rs3746266A>G and rs6510997C>T) investigated previously (Choong et al., 2013) were used 
in the current study. 
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Patients and methods: 
The associations between CRTC1 polymorphisms and obesity markers were first tested in the 
PsyCoLaus sample and tested for replication in the Radiant and NESDA/NTR study. 
Supplementary Table S1 presents the main similarities and differences between these 
samples.  
Discovery cohort: CoLaus|PsyCoLaus 
Participants aged 35 to 75 years in this population-based cohort study (CoLaus; n=6,734) 
were recruited between June 2003 and May 2006 in Lausanne, Switzerland as previously 
described (Firmann et al., 2008). The assessments at baseline and at the first follow-up 
included cardiovascular risk factors such as BMI, fat mass, blood pressure, glucose and lipid 
profiles. In addition, a genome-wide association study was performed in all Caucasians (91% 
of the sample). All participants of CoLaus were asked to also participate in the psychiatric 
evaluations (PsyCoLaus (Preisig et al., 2009)), which included the semi-structured Diagnostic 
Interview for Genetic Studies (DIGS)(Nurnberger et al., 1994; Preisig et al., 1999). The 
assignment of the lifetime diagnosis of MDD and the subtyping into atypical and non-atypical 
MDD was performed according to DSM-IV criteria. Complete physical and psychiatric data 
were available for 3,354 participants aged 35 to 65 year-old who completed the psychiatric 
evaluation either at the baseline or the first follow-up (ntotal=3362). 1434 cases of lifetime 
depression were compared with 1,920 controls with no previous history of depression. 
Genotyping for the CoLaus/PsyCoLaus subjects was performed using the Affymetrix 
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GeneChipR Human Mapping 500K array set. The CRTC1 rs6510997C>T SNP was directly 
genotyped (Choong et al., 2013). The CRTC1 rs7257846T>C, which is in linkage disequilibrium 
(LD) with rs3746266A>G (r2=0.93), was imputed and analyzed (r2hat value was 0.70).  
The Institutional Ethics Committee of the University of Lausanne approved the CoLaus and 
subsequently the PsyCoLaus study. All participants signed a written informed consent to 
participate in the study. 
- The Radiant study 
The Radiant study was founded from three studies: the Depression Case–Control (DeCC) 
study, Depression Network (DeNT) study and the Genome-Based Therapeutic Drugs for 
Depression (GENDEP) study. The DeCC study is a multicentre case-control study conducted 
over three investigative sites in UK (London, Cardiff and Birmingham)(Cohen-Woods et al., 
2009). The DeNT study is a family-based study that recruited sibling pairs affected with 
unipolar depression from eight European clinical sites and one in the USA (Farmer et al., 
2004; McGuffin et al., 2005). Participants in the DeCC and DeNT studies were included if they 
had lifetime diagnosis of two or more episodes of MDD of at least moderate severity. 
Subjects in the GENDEP study were recruited from nine European centers if they 
experienced at least one depressive episode of at least moderate severity (Uher et al., 2009). 
Diagnosis of MDD was defined as of illness fulfilling ICD–10 and/or DSM–IV criteria and was 
ascertained using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview 
in all three studies (Wing et al., 1990). Control subjects were recruited via the Medical 
Research Council general practice research framework (Sham et al., 2000). They were 
screened for lifetime absence of any psychiatric disorder using a modified version of the Past 
History Schedule(McGuffin et al., 1986). Self-reported height and weight were obtained from 
participants in the MDD group via the SCAN interview and from the controls via telephone 
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interview. The reliability of self-report of height and weight was assessed in the GENDEP 
dataset (n=811) where also height and weight were measured. The correlations for 
measured versus self-reported height, weight and BMI were 0.97, 0.95 and 0.95, respectively 
(Hung et al., 2014; Hung et al., 2015). All cases and controls were of white European 
ancestry. Genotyping for the Radiant subjects was performed using the Illumina 
HumanHap610-Quad BeadChips by the Centre National de Génotypage (CNG), Evry, France, 
as previously described (Lewis et al., 2010). CRTC1 rs3746266A>G was successfully imputed 
using the Beagle Program (BEAGLE Version 3.0 Copyright (c) 2007–2010 Brian L Browning), 
with imputation quality >0.8. The CRTC1 rs2075017T>C, which is in complete linkage 
disequilibrium (LD) with the rs6510997C>T, was also selected for the association analyses.  
Approval was obtained from the local research ethics committees/institutional research 
boards of all of the participating sites. All participants provided written informed consent. 
- NESDA/NTR study: 
This sample consisted of 4,663 unrelated participants of European ancestry from the 
Netherlands Study of Depression and Anxiety (NESDA)(Penninx et al., 2008) (1,636 cases and 
425 controls) and from the Netherlands Twin Registry (NTR)(Boomsma et al., 2006) (132 
cases and 2,470 controls). The diagnosis of lifetime and/or current MDD according to DSM-IV 
was ascertained using the Composite Interview Diagnostic Instrument (WHO WMH-CIDI, 
2015). Weight and height were measured at the study clinic during the visit for NESDA 
(Penninx et al., 2008), and during the home visit for NTR-Biobank (Willemsen et al., 2010). 
Genotyping was performed on multiple chip platforms in (partially overlapping) different 
subsets of the total sample (Affymetrix-Perlegen 5.0, Illumina 370K, Illumina 660K, Illumina 
Omni 1M and Affymetrix 6.0) and data were imputed using the 1000 Genomes phase 1 
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INTEGRATED RELEASE version 3 ALL panel (r2hat value was 0.99 for rs6510997C>T and 0.77 
for rs3746266A>G).  
The NESDA/NTR study was approved by the Central Ethics Committee on Research Involving 
Human Subjects of the VU University Medical Center, Amsterdam, and all subjects provided 
written informed consent. 
 
Statistical analysis: 
For association studies, chi-square (Chi2) or Fisher exact tests for binomial variables were 
used. Differences in genotype frequencies as well as deviation from Hardy-Weinberg 
equilibrium were assessed using Chi² test. All genetic analyses for CRTC1 SNPs were 
performed using a dominant model (wild type vs. variant allele carriers), the same model 
used for the previously mentioned psychiatric samples (Choong et al., 2013). 
Multivariable regression analyses were used to test the association between the CRTC1 SNPs 
and MDD adjusting for age, sex and BMI. For PsyCoLaus data, a Generalized Linear Model 
(GLM) adjusted for age and sex was used to test the association between CRTC1 
rs6510997C>T polymorphism and obesity markers (BMI, fat mass and waist circumference) 
using SAS 9.3 version (SAS Institute Inc., Cary, NC, USA). In a first step, we tested for the 
interaction between CRTC1 SNPs and MDD status for an effect on obesity markers. For the 
Radiant and NESDA/NTR studies BMI was the only available obesity marker. For the data of 
these studies, linear regression models adjusted for age, sex and principal components were 
used to test the association between CRTC1 polymorphisms and BMI. 
 
Results: 
Demographic characteristics of the study samples: 
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General characteristics of the PsyCoLaus sample are presented in Supplementary Table S2.  
The Radiant study included 3148 subjects (2,338 cases and 810 controls), mean 
age±standard deviation (s.d.) was 43.9±12.8 years. Females represent nearly 68% of the 
study sample. Mean BMI in the total study sample was 25.9 kg/m2 (s.d. 5.4). The NESDA/NTR 
study included 4,663 subjects, mean age±s.d. was 42.7±14.0 years. Females represent nearly 
64% of the study sample. Mean BMI in the total study sample was 25.0 kg/m2 (s.d. 4.5).  
 
CRTC1 polymorphisms and MDD: 
Genotype distribution in the overall study samples and among MDD cases and controls are 
presented in Table 1. Genotype distribution did not differ between MDD cases and controls 
in any of the three studies (Table 1). Multivariate analyses adjusted for age and sex 
confirmed the absence of an association between CRTC1 polymorphisms and MDD in the 
three studies (data not shown). 
 
CRTC1 polymorphisms and obesity markers: 
PsyCoLaus  
CRTC1 rs6510997C>T was significantly associated with fat mass in the global PsyCoLaus 
sample (Table 2). We observed interactions between CRTC1 rs6510997C>T and sex (p=0.03) 
as well as between this SNP and MDD status (p=0.01) regarding the fat mass, indicating a 
significantly stronger effect of this genetic variant in females and in subjects with MDD. 
Indeed, this SNP was significantly associated with lower fat mass in females but not in males. 
Similarly, this SNP was significantly associated with lower fat mass in subjects with MDD but 
not in controls (Table 2). Additionally, the 3-way interaction between CRTC1 rs6510997C>T, 
sex and MDD regarding the fat mass was not significant (p=0.54). In females, we did not find 
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an interaction between the CRTC1 rs6510997C>T SNP and menopausal status and among 
depressed subjects there was no interaction between this SNP and the atypical depression 
subtype to affect the fat mass. Regarding the BMI and waist circumference there was no 
evidence of an interaction between CRTC1 rs6510997C>T and sex or MDD status and the 
SNP was not associated with these obesity markers (Table 2). 
No difference on the associations between CRTC1 rs6510997C>T and fat mass was noticed 
by adjusting the GLM model for other available co-variables that could affect the gene 
association with obesity markers, like socioeconomic status, drug dependence, alcohol 
consumption, former and current tobacco consumer (Supplementary Table S3). Nearly the 
same associations with obesity markers were observed in PsyCoLaus for CRTC1 
rs7257846T>C (in strong LD with rs3746266A>G, r2=0.93)(Supplementary Table S4). 
 
The Radiant and NESDA/NTR studies: 
The CRTC1 rs3746266A>G SNP was associated with BMI in the total Radiant sample and 
exclusively in females (Table 3). By stratifying MDD cases and controls, the protective effect 
of the rs3746266G-allele was only observed in MDD cases, while no association was 
observed in controls. A weak association was observed between CRTC1 rs2075017T>C (in 
complete LD with the rs6510997C>T) and BMI in the Radiant sample (Table 3). Regarding the 
NESDA/NTR study, CRTC1 SNPs were not associated with BMI (Table 4). 
 
Discussion: 
We previously showed a protective effect of the variant CRTC1 rs3746266G-allele on 
increased BMI in three independent psychiatric samples (Choong et al., 2013). The same 
protective effect was also observed in a population-based sample (CoLaus) between the 
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rs6510997T-allele (in a strong LD with the rs3746266G-allele) and fat mass. However, the 
effect of the SNP was weaker compared to the psychiatric samples (Choong et al., 2013). In 
the present study, we were able to show in the psychiatrically evaluated sub-sample of 
CoLaus (PsyCoLaus) that the effect of CRTC1 rs6510997C>T on fat mass was restricted to 
subjects with a lifetime history of MDD. In these subjects, the CRTC1 rs6510997T-allele 
showed a significant protective effect for the fat mass. Although there was no significant 
interaction between the CRTC1 SNPs and MDD, similar trend regarding the BMI was 
observed in the Radiant sample (no fat mass data available in this sample), which included 
more severe treated cases with lifetime recurrent depression. The CRTC1 rs3746266A>G SNP 
only reached the level of statistical significance in MDD cases. However, these results could 
not be replicated in a third case-control sample with lifetime depression, the NESDA/NTR 
study. 
 
CRTC1 rs6510997C>T was associated with fat mass exclusively among depressive cases but 
not unaffected individuals in the PsyCoLaus sample. This association in depressed subjects 
did not differ in function of the depression subptypes (atypical versus others). Such an 
association with the BMI was not observed in the whole PsyCoLaus sample, but CRTC1 SNPs 
were associated with BMI in the Radiant study. BMI may less accurately capture adiposity 
than estimated fat mass using bioimpedance (Marques-Vidal et al., 2009; Prentice and Jebb, 
2001). Using the whole CoLaus sample, previous work established that fat mass enables 
capture of 3 times more subjects with high cardiovascular risk than BMI(Marques-Vidal et 
al., 2009) and we also showed that this sample is better powered to detect an association of 
the rs6510997C>T SNP with fat mass than with BMI (Choong et al., 2013). In the psychiatric 
samples, based on subjects at high risk of metabolic abnormalities because of the disorder 
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and of the psychotropic medications, an association between CRTC1 SNPs and BMI could be 
observed (Choong et al., 2013). Accordingly, the association between CRTC1 SNPs and BMI 
observed in the Radiant study could be explained by the higher degree of severity of the 
disorder in this sample compared to that in the PsyCoLaus. Interestingly, post hoc analysis 
also revealed a significant protective effect of the CRTC1 rs6510997C>T SNP on BMI and 
waist circumference in PsyCoLaus subjects with MDD (but not in the overall sample)  which 
would be in line with our hypothesis that the impact of CRTC1 variants on adiposity markers 
is restricted to affected subjects. 
 
CRTC1 SNPs were associated with obesity markers in both PsyCoLaus and Radiant studies, 
but the association was entirely attributable to MDD cases. On the other hand, CRTC1 SNPs 
were not associated with BMI in the NESDA/NTR study, neither in the whole sample, nor in 
the stratified MDD case-control analyses. Previously, PsyCoLaus and DeCC (from the Radiant 
study) samples detected a protective effect of the FTO rs9939609-A variant on MDD 
(Samaan et al., 2013), while in the NESDA/NTR study the SNP was positively associated with 
MDD, especially in the atypical depression subtype (Milaneschi et al., 2014). Therefore, an 
inconsistency was already observed before for these studies which could be partly explained 
by the heterogeneity of depression in genetic association studies. 
 
Obesity results from an imbalance between energy intake and energy expenditure. Recent 
studies have shown that mice lacking the Crtc1 gene eat more and have less energy 
expenditure than wild-type mice, thus developing an obese feature, including obesity-
related metabolic complications, under normal diets (Altarejos et al., 2008; Breuillaud et al., 
2009). These results suggest that CRTC1 is playing a major role in the hypothalamic control 
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of food intake. CRTC1 is mainly expressed in the brain (Altarejos et al., 2008; Breuillaud et 
al., 2009; Conkright et al., 2003; Kovacs et al., 2007; Wu et al., 2006) where it may modulate 
leptin anorexic effect in the hypothalamus. In the cell, the inactive phosphorylated form of 
CRTC1 is sequestered in the cytoplasm, and its migration to the nucleus requires the 
concomitant activation of the phosphatase calcineurin and the inactivation of kinases of the 
5’ adenosine monophosphate-activated protein kinase (AMPK) family (Altarejos and 
Montminy, 2011). Interestingly, psychotropic drugs may increase weight by selective and 
potent stimulation of hypothalamic AMPK (Minokoshi et al., 2004) which has been shown to 
regulate food intake and reverse the actions of the anorexigenic hormone leptin (Kim et al., 
2007) 
 
In the PsyCoLaus sample, an interaction between CRTC1 SNP and sex was observed 
regarding the fat mass and the protective effect of the SNP was mainly observed in females 
from the global sample. The same protective effect of CRTC1 SNP on BMI was also observed 
in females from the global Radiant sample. This is in line with our previous results in the 
psychiatric and CoLaus samples (Choong et al., 2013). This stronger association found in 
females compared to males could be caused by a differential role of the leptin mediating 
satiety pathway in the enhancement of CRTC1 activity. Women have much higher leptin 
levels than men (Rosenbaum et al., 1996) and female sex was found to predict stronger 
weight gain during psychotropic treatment (Gebhardt et al., 2009). A hypothetical 
mechanism of the effect of CRTC1 and its interaction with sex hormones was published 
previously (Choong et al., 2013). Additionally, a meta-analysis of GWAS reported an 
association of an intronic SNP of CRTC1 (rs10423674A>C) with the age of menarche (Elks et 
al., 2010), supporting a potential interaction between sex hormones and CRTC1.  
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The CRTC1 SNPs were not associated with depression in our three MDD case-control studies. 
Animal models lacking the Crtc1 gene showed behavioral abnormalities and depression-
related behavior (Breuillaud et al., 2012), but this finding could not be translated in our 
study. However, the functional activities of these SNPs in humans are still unknown and 
possibly the complete absence of the CRTC1 gene could lead to the observed behavioral 
disturbances in animal models, which is probably not the case for effect of the tested SNPs 
on CRTC1 expression. On the other hand, the observed effect of the CRTC1 SNPs on obesity 
markers was uniquely detected in subjects with MDD. The lack of association between 
CRTC1 SNPs and obesity markers in controls from the PsyCoLaus and the Radiant samples 
explains the weak association previously found in the population-based sample (Choong et 
al., 2013). It also confirms our hypothesis in which psychiatric illness and/or treatment with 
potentially weight gain-inducing psychotropic drugs could play a role in genetically mediated 
energy homeostasis and that the effect of CRTC1 variations on obesity markers was 
unmasked in this group of subjects. Interestingly, a study in animal models (Mastronardi et 
al., 2011) showed that rats exposed to a high-fat diet after stress and treatment for a short 
period with antidepressants, to have more body weight and size from 17 to 22 weeks 
following antidepressant discontinuation compared to rats with the same conditions but 
treated with saline (Mastronardi et al., 2011). These findings support our concept of 
persistent, long-term effects of pharmacological–environment interactions on body weight 
regulation, even if the exposure to these medications was in any period in their lifetime. 
 
This study has several limitations. Estimated fat mass using bioimpedance was only 
measured in the PsyCoLaus sample while only BMI was the only adiposity marker measured 
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in the replication samples. Additionally, height and weight were self-reported in the Radiant 
study, which might influence the accuracy of BMI measurements in this sample, although 
the reliability of self-report of height and weight was assessed in the GENDEP dataset. 
Psychotropic medications were not available in the Radiant sample, therefore, associations 
between CRTC1 SNPs and BMI in treated vs. untreated cases could not be calculated. Both 
CRTC1 SNPs (rs6510997C>T and rs3746266A>G) were not always available in our three case-
control samples; however, SNPs with nearly complete LD (r2>0.9) were selected and used as 
proxies, and results from these proxies could be generalized to our 2 CRTC1 SNPs (meaning 
that the genotype present at one locus of the SNPs in LD is independent of the genotype at 
the second locus, both SNPs having the same allele frequency and could represent each 
other). On the other hand, SNPs were not always directly genotyped and different 
imputation methods with different imputation qualities were used which can potentially 
influence the results on the associations between different imputated CRTC1 SNPs and 
obesity markers in our studies. 
In conclusion, we showed in this study that CRTC1 polymorphisms play no role in obesity 
markers in the general population and that the weak effect previously reported was driven 
by cases diagnosed with lifetime MDD. CRTC1 seems to play an important role in the high 
prevalence of overweight and obesity specifically in psychiatric samples, a population at risk 
of developing obesity because of the disease itself and/or the medications. However, CRTC1 
seems not to be implicated directly in the development of psychiatric diseases.  
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Table 1: Genotype distribution in the total study samples, among MDD subjects and controls 
Patients Total                         N (%) HWE 
PsyCoLaus      
rs6510997C>T $  CC CT TT  
Total 3347 2128 (63.6) 1092 (32.6) 127 (3.8) 0.37 
MDD cases 1431 912 (63.7) 468 (32.7) 51 (3.6)  
Controls 1916 1216 (63.5) 624 (32.6) 76 (3.9)  
      
The Radiant study      
rs3746266A>G  AA AG GG  
Total 2842 2173 (76.5) 626 (22.0) 43 (1.5) 0.78 
MDD cases 2142 1637 (76.4) 468 (21.9) 37 (1.7)  
Controls 700 536 (76.5) 158 (22.6) 6 (0.9)  
      
rs2075017T>C $  TT TC CC  
Total 2160 1357 (62.8) 720 (33.3) 83 (3.9) 0.30 
MDD cases 1352 849 (62.8)  450 (33.3) 53 (3.9)  
Controls 808 508 (62.9)      270 (33.4) 30 (3.7)  
      
NESDA/NTR 
study 
     
rs3746266A>G  AA AG GG  
Total 4663 3235 (69.4) 1306 (28.0) 122 (2.6) 0.47 
MDD cases 1768 1234(69.8) 485 (27.4) 49 (2.8)  
Controls 2895 2001 (69.1) 821 (28.5) 73 (2.5)  
      
rs6510997C>T  CC CT TT  
Total 4663 2952 (63.3) 1522 (32.6) 189 (4.1) 0.68 
MDD cases 1768 1124 (63.6)  567 (32.1) 77 (4.4)  
Controls 2895 1828 (63.1)      955 (33.0) 112 (3.9)  
      
22 
 
MDD: Major depressive disorder, N: number, HWE: Hardy-Weinberg Equilibrium 
$ Both SNPs are in complete linkage disequilibrium (r2=1) 
 
Table 2: Association between CRTC1 rs6510997C>T polymorphism and fat mass, BMI and waist 
circumference in the PsyCoLaus sample, among sex-stratified and MDD subjects and controls 
               Fat mass£$                   BMI§   Waist 
circumference§ 
 n 
Estimates 
(95% C.I.) 
p-
value 
 
Estimates 
(95% C.I.) 
p-
value 
 
Estimates 
(95% C.I.) 
p-
value 
All subjects 3362 -0.66 (-1.28 
to -0.04) 
0.04  -0.28 (-0.60 to 
0.04) 
0.09  -0.70 (-1.64 
to 0.24) 
0.14 
Males 1576 -0.03 (-0.56 
to 0.51) 
0.92  
 
  
 
 
Females 1786 -1.08 (-1.81 
to -0.34) 
0.004  
 
  
 
 
Subjects with 
MDD 
1434 -1.32 (-2.07 
to -0.57) 
<0.001       
Controls 1920 -0.01 (-0.60 
to 0.57) 
0.97       
Models were adjusted for age and sex (when appropriate). 
BMI: body mass index, C.I.: confidence interval, MDD: Major depressive disorder 
£ CRTC1 rs6510997C>T and MDD status interaction regarding fat mass: p= 0.014 
$ CRTC1 rs6510997C>T and sex interaction regarding fat mass: estimate: p=0.026 
§ CRTC1 rs6510997C>T and MDD status and/or sex interactions regarding BMI and waist circumference: p>0.05 
Table 3: Association between CRTC1 polymorphisms and BMI in the total, sex-stratified sample and in 
depressive cases and controls of the Radiant study sample: 
                               rs3746266A>G£  rs2075017T>C
$ 
 n Estimates (95% C.I.) P  n Estimates (95% C.I.) p 
All subjects& 2822 -0.67 (-1.13 to -0.21) 0.004  2136 -0.50 (-0.95 to -0.05) 0.03 
Male 909 -0.38 (-1.05 to 0.30) 0.28  713 -0.25 (-0.93 to 0.42) 0.46 
Female 1916 -0.79 (-1.38 to -0.21) 0.008  1424 -0.62 (-1.20 to -0.04) 0.04 
Subjects with MDD 2138 -0.75 (-1.30 to -0.21) 0.007  1346 -0.59 (-1.20 to 0.02) 0.06 
Controls 684 -0.41 (-1.20 to 0.39) 0.32  790 -0.32 (-0.95 to 0.31) 0.32 
Model were adjusted for age and sex (when appropriate) and principal components 
C.I.: confidence interval, MDD: Major depressive disorder 
& Available subjects with clinical and genetic data. 
£CRTC1 rs3746266A>G and MDD status and/or sex interactions regarding BMI: p>0.05 
$CRTC1 rs2075017T>C and MDD status and/or sex interactions regarding BMI: p>0.05 
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Table 4: Association between CRTC1 polymorphisms and BMI in the total, sex-stratified sample and in 
depressive cases and controls of the NESDA/NTR study sample: 
                                                        rs3746266A>G           rs6510997C>T 
 n Estimates (SE) P  Estimates (SE) p 
All subjects 4663 -0.047 (0.130) 0.73  0.014 (0.130) 0.91 
Male 1676 0.072 (0.202) 0.72  -0.053 (0.193) 0.78 
Female 2987 -0.121 (0.179) 0.50  0.046 (0.172) 0.79 
Subjects with 
MDD 
1768 0.038 (0.256) 0.88  0.166 (0.245) 0.50 
Controls 2895 -0.076 (0.150) 0.61  -0.054 (0.144) 0.71 
Model were adjusted for age and sex (when appropriate) and principal components 
SE: standard error, MDD: Major depressive disorder 
 
 
24 
 
 
Highlights: 
 Psychiatric disorders may share common etiological pathways with obesity. 
 CRTC1 polymorphisms were not associated with major depression disorder (MDD) in three 
case-control samples with MDD.  
 In PsyCoLaus, CRTC1 rs6510997C>T was significantly associated with lower fat mass in 
females but not in males. 
 In PsyCoLaus, CRTC1 rs6510997C>T was significantly associated with lower fat mass in 
subjects with MDD but not in controls. 
 CRTC1 polymorphisms were associated with BMI in MDD cases from the Radiant study, but 
not from the NESDA/NTR study. 
 CRTC1 polymorphisms seem to play a role with obesity markers only in individuals with MDD 
but not in non-depressive individuals. 
 
 
